Spark Therapeutics (ONCE) Lifted to “Strong-Buy” at ValuEngine

ValuEngine upgraded shares of Spark Therapeutics (NASDAQ:ONCE) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday.

Several other research analysts have also commented on ONCE. Credit Suisse Group restated an outperform rating and set a $75.00 price target (up from $61.00) on shares of Spark Therapeutics in a research report on Thursday, March 8th. Mizuho set a $79.00 price target on Spark Therapeutics and gave the stock a buy rating in a research report on Thursday, March 29th. William Blair restated a buy rating on shares of Spark Therapeutics in a research report on Thursday, April 19th. Chardan Capital lowered Spark Therapeutics from a buy rating to a neutral rating and raised their price target for the stock from $80.00 to $85.00 in a research report on Monday, April 23rd. Finally, Cantor Fitzgerald restated a buy rating and set a $103.00 price target (up from $100.00) on shares of Spark Therapeutics in a research report on Monday, April 30th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $76.95.

ONCE stock opened at $82.76 on Tuesday. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -10.85 and a beta of 2.53. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $94.00.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.80). Spark Therapeutics had a negative return on equity of 51.76% and a negative net margin of 935.38%. The firm had revenue of $15.68 million for the quarter, compared to analysts’ expectations of $51.55 million. During the same quarter in the prior year, the business earned ($1.70) earnings per share. The company’s quarterly revenue was up 1134.6% on a year-over-year basis. equities analysts expect that Spark Therapeutics will post -3.46 EPS for the current year.

In related news, COO John Furey sold 13,277 shares of Spark Therapeutics stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $82.52, for a total value of $1,095,618.04. Following the completion of the transaction, the chief operating officer now directly owns 2,277 shares in the company, valued at $187,898.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 40,000 shares of company stock valued at $3,200,466. 5.90% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its holdings in Spark Therapeutics by 90.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,100 shares of the biotechnology company’s stock worth $140,000 after buying an additional 1,000 shares during the last quarter. Silvant Capital Management LLC purchased a new stake in Spark Therapeutics during the 1st quarter worth about $141,000. Commonwealth Equity Services LLC purchased a new stake in Spark Therapeutics during the 1st quarter worth about $240,000. Amalgamated Bank purchased a new stake in Spark Therapeutics during the 1st quarter worth about $246,000. Finally, Centaurus Financial Inc. purchased a new stake in Spark Therapeutics during the 1st quarter worth about $256,000.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply